ATE105867T1 - Immunaffinitäts-reinigungssystem. - Google Patents

Immunaffinitäts-reinigungssystem.

Info

Publication number
ATE105867T1
ATE105867T1 AT88900409T AT88900409T ATE105867T1 AT E105867 T1 ATE105867 T1 AT E105867T1 AT 88900409 T AT88900409 T AT 88900409T AT 88900409 T AT88900409 T AT 88900409T AT E105867 T1 ATE105867 T1 AT E105867T1
Authority
AT
Austria
Prior art keywords
complex
protein
monoclonal antibody
immunaffinity
sequence
Prior art date
Application number
AT88900409T
Other languages
English (en)
Inventor
Thomas P Hopp
Kathryn S Prickett
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25481081&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE105867(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of ATE105867T1 publication Critical patent/ATE105867T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/145—Colony stimulating factor
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/30—Signal or leader sequence

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • External Artificial Organs (AREA)
AT88900409T 1986-12-19 1987-12-04 Immunaffinitäts-reinigungssystem. ATE105867T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/944,261 US4851341A (en) 1986-12-19 1986-12-19 Immunoaffinity purification system

Publications (1)

Publication Number Publication Date
ATE105867T1 true ATE105867T1 (de) 1994-06-15

Family

ID=25481081

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88900409T ATE105867T1 (de) 1986-12-19 1987-12-04 Immunaffinitäts-reinigungssystem.

Country Status (8)

Country Link
US (1) US4851341A (de)
EP (1) EP0335899B1 (de)
JP (1) JP2665359B2 (de)
AT (1) ATE105867T1 (de)
AU (1) AU1056188A (de)
CA (1) CA1307752C (de)
DE (1) DE3789873T2 (de)
WO (1) WO1988004692A1 (de)

Families Citing this family (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5853978A (en) * 1985-12-04 1998-12-29 Genentech, Inc. Molecularly cloned acquired immunodeficiency syndrome polypeptides and methods of use
US6534285B1 (en) 1984-12-24 2003-03-18 Genentech, Inc. Molecularly cloned acquired immunodeficiency syndrome polypeptides and their methods of use
US8597910B1 (en) 1985-04-11 2013-12-03 Children's Medical Center Corporation DNA encoding Von Willebrand Factor (VWF) and methods and cells for producing VFW, and VFW produced by the DNA, methods and cells
US5851991A (en) * 1987-08-31 1998-12-22 The Regents Of The University Of California Therapeutic use of the retinoblastoma susceptibility gene product
US5070013A (en) * 1988-05-31 1991-12-03 Schering Corporation Immunochemical assay for human granulocyte-macrophage colony stimulating factor
US5298599A (en) * 1988-12-30 1994-03-29 Oklahoma Medical Research Foundation Expression and purification of recombinant soluble tissue factor
US5639624A (en) * 1989-03-14 1997-06-17 Board Of Regents Of The University Of Nebraska Monoclonal antibodies specific for metallic cations and method therefor
US6143508A (en) * 1989-06-29 2000-11-07 Rhone-Poulenc Rorer Pharmaceuticals Inc. Device and process for cell capture and recovery
CA1340565C (en) 1989-06-29 1999-05-25 Thomas B. Okarma Device and process for cell capture and recovery
US5179007A (en) * 1989-07-07 1993-01-12 The Texas A & M University System Method and vector for the purification of foreign proteins
DK0511978T3 (da) * 1990-01-24 1994-08-01 Upjohn Co Fremgangsmåde til rensning af rekombinante polypeptider
AT396939B (de) * 1990-05-29 1993-12-27 Alois Dipl Ing Dr Jungbauer Komplexes virales antigen von hiv-1 bindendes rekombinantes protein
NZ240558A (en) 1990-11-14 1994-11-25 Smithkline Beecham Corp Recombinant feline coronavirus s proteins useful in diagnosis and vaccination against feline peritonitis virus disease
US5292646A (en) * 1991-02-06 1994-03-08 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin and thioredoxin-like molecules
DE4105400A1 (de) * 1991-02-21 1992-08-27 Behringwerke Ag Definierte beschichtung mit rekombinanten fusionsproteinen aus konstantem fusionspartner und variablem antigenanteil in diagnostischen testsystemen
US5939531A (en) * 1991-07-15 1999-08-17 Novartis Corp. Recombinant antibodies specific for a growth factor receptor
US6028177A (en) * 1991-10-04 2000-02-22 Washington University Methods of detecting single-chain forms of the glycoprotein hormone quartet
US20040063093A1 (en) * 1992-04-08 2004-04-01 Pfizer, Inc. Recombinant feline coronavirus S proteins
US5316921A (en) * 1992-05-18 1994-05-31 Genentech, Inc. Single-chain hepatocyte growth factor variants
ATE222603T1 (de) * 1992-05-18 2002-09-15 Genentech Inc Hepatozytwachstumfaktor variante
JP3662948B2 (ja) * 1992-12-09 2005-06-22 ニユー・イングランド・バイオレイブス・インコーポレイテツド 改質タンパク質及びその製造法
US6287784B1 (en) 1993-11-23 2001-09-11 Genentech, Inc. Kinase receptor activation assay
US6025145A (en) * 1993-11-23 2000-02-15 Genentech, Inc. Kinase receptor activation assay
US6492106B1 (en) * 1994-06-27 2002-12-10 The Johns Hopkins University Mammalian proteins that bind to FKBP12 in a rapamycin-dependent fashion
WO1996010649A1 (en) * 1994-09-30 1996-04-11 Southwest Foundation For Biomedical Research Isolated human hepatitis b virus polymerase and uses thereof
US5731425A (en) * 1994-10-28 1998-03-24 Eastman Kodak Company Polypeptide surface marker for cells
US5770442A (en) 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US6054289A (en) 1995-08-30 2000-04-25 Human Genome Sciences, Inc. Polynucleotides encoding human ADA2
US5807708A (en) * 1996-07-30 1998-09-15 Millennium Pharmaceuticals, Inc. Conservin nucleic acid molecules and compositions
US20020102706A1 (en) * 1997-06-18 2002-08-01 Genentech, Inc. Apo-2DcR
CA2291323A1 (en) * 1997-05-28 1998-12-03 Genvec, Inc. Alternatively targeted adenovirus
US20030022293A1 (en) * 1997-09-18 2003-01-30 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2002516061A (ja) 1997-10-14 2002-06-04 ダーウィン モレキュラー コーポレイション チミジンキナーゼ変異体ならびにチミジンキナーゼ活性およびグアニル酸キナーゼ活性を有する融合タンパク質
CA2315977A1 (en) * 1997-12-24 1999-07-08 Ludwig Institute For Cancer Research Expression vectors and cell lines expressing vascular endothelial growth factor d, and method of treating melanomas
CA2263784A1 (en) 1998-03-23 1999-09-23 Megabios Corporation Dual-tagged proteins and their uses
EP1105417A4 (de) * 1998-08-26 2002-08-07 Salem Teikyo University P10 polypeptid des borna-disease-virus (bdv) und die dafür kodierende nukleinsäure und ihre verwendung für diagnostische und impfzwecke
ATE481487T1 (de) 1998-11-27 2010-10-15 Ucb Sa Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
US6911429B2 (en) * 1999-04-01 2005-06-28 Transition Therapeutics Inc. Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US6864235B1 (en) 1999-04-01 2005-03-08 Eva A. Turley Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US6379903B1 (en) 1999-10-08 2002-04-30 Sigma-Aldrich Co. Purification of recombinant proteins fused to multiple epitopes
EP1939203B1 (de) 2000-04-25 2014-11-19 ICOS Corporation Hemmer der delta-Isoform der menschlichen Phosphatidyl-Inositol-3-Kinase
GEP20084317B (en) 2000-04-25 2008-02-25 Icos Corp Inhibitors of human phosphatidyl-inositol 3-kinase delta
US6756215B1 (en) 2000-10-20 2004-06-29 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Functionalized TGF-β fusion proteins
US6977293B1 (en) 2000-11-03 2005-12-20 Ceres, Inc. Chimeric polypeptides
WO2002039083A2 (en) * 2000-11-08 2002-05-16 Science & Technology Corporation @ Unm Fluorescence and fret based assays for biomolecules on beads
WO2002061064A2 (de) * 2001-02-01 2002-08-08 Roche Diagnostics Gmbh Verfahren zur herstellung von rekombinantem trypsin
DE10112851C1 (de) 2001-03-16 2002-10-10 Gsf Forschungszentrum Umwelt Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen
EP1967525B1 (de) 2001-05-08 2012-11-14 Darwin Molecular Corporation Verfahren zur Regulierung der Immunfunktion in Primaten unter Verwendung des foxp3-Proteins
CA2451654A1 (en) * 2001-06-22 2003-01-03 Ceres, Inc. Chimeric histone acetyltransferase polypeptides
US6902914B2 (en) * 2001-09-28 2005-06-07 Sigma-Aldrich, Co. Recombinant DNA processes using a dNTP mixture containing modified nucleotides
US7799561B2 (en) * 2002-06-12 2010-09-21 Sigma-Aldrich, Co. Affinity peptides and method for purification of recombinant proteins
JP4694840B2 (ja) 2002-09-09 2011-06-08 アルボー ビータ コーポレーション 子宮頸部癌を検査する方法
US20050233307A1 (en) 2002-09-12 2005-10-20 Kyle Gee Site-specific labeling of affinity tags in fusion proteins
US20040137643A1 (en) * 2002-12-02 2004-07-15 John Humphreys Immunodetection and quantification methods
US7365240B2 (en) * 2003-02-05 2008-04-29 Divergence, Inc. Nucleic acids encoding anthelmintic agents and plants made therefrom
EP1656443A4 (de) * 2003-05-02 2007-06-06 Sigma Aldrich Co Festphasen-zellyse und einfangplattform
US7368629B2 (en) * 2004-02-04 2008-05-06 Divergence, Inc. Nucleic acids encoding anthelmintic agents and plants made therefrom
WO2005113556A1 (en) 2004-05-13 2005-12-01 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
WO2006026248A1 (en) * 2004-08-25 2006-03-09 Sigma-Aldrich Co. Compositions and methods employing zwitterionic detergent combinations
US7741053B2 (en) * 2005-05-13 2010-06-22 Sigma-Aldrich Co. Processes for purification of recombinant proteins
US20090275481A1 (en) * 2005-06-17 2009-11-05 Pfizer, Inc. Anchored Transferrin Fusion Protein Libraries
ZA200710330B (en) * 2005-06-17 2009-12-30 Wyeth Corp Methods of purifying FC region containing proteins
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
EP1878744A1 (de) * 2006-07-13 2008-01-16 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Epitope-Tag für an der Oberfläche exprimierte T-Zell Rezeptor Proteine, deren Anwendung und Verfahren zur Selection von Wirtszellen, die sie exprimieren
WO2008044378A1 (en) 2006-10-11 2008-04-17 Oriental Yeast Co., Ltd. Reagent containing fused protein of soluble rankl with epitope tag
MX2009006398A (es) 2006-12-12 2009-06-23 Biorexis Pharmaceutical Corp Genotecas de proteinas de fusion de transferrina.
WO2008118386A2 (en) * 2007-03-27 2008-10-02 Merck & Co., Inc. Method for detecting autoprocessed, secreted pcsk9
ES2420969T3 (es) 2007-06-22 2013-08-28 B.R.A.H.M.S Gmbh Procedimiento para la detección de analitos
DE102007037068A1 (de) 2007-08-04 2009-02-05 Brahms Aktiengesellschaft Verfahren zur Detektion von Analyten
DE102007029766A1 (de) 2007-06-22 2008-12-24 Brahms Aktiengesellschaft Verfahren zur Detektion von Analyten
ES2595638T3 (es) 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
CN101952292A (zh) * 2007-11-13 2011-01-19 艾科斯有限公司 人磷脂酰肌醇3-激酶δ的抑制剂
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
DK2352756T3 (da) 2008-11-24 2012-12-03 Helmholtz Zentrum Muenchen Højaffin T-cellereceptor og anvendelse af denne
WO2010089412A1 (en) 2009-02-09 2010-08-12 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) Repertoire of allo-restricted peptide-specific t cell receptor sequences and use thereof
EP2258719A1 (de) 2009-05-19 2010-12-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Mehrfachziel-T-Zellen-Rezeptor
EP2539337A1 (de) 2010-02-22 2013-01-02 F. Hoffmann-La Roche AG Pyrido-[3,2-d-]pyrimidin-pi3k-delta-hemmer-verbindungen und verfahren zu ihrer verwendung
ES2536780T3 (es) 2010-07-14 2015-05-28 F. Hoffmann-La Roche Ag Compuestos de purina selectivos para I3 p110 delta, y métodos de uso
EP2647706B1 (de) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigenbindende moleküle zur wiederholten bindung an mehrere antigenmoleküle
MX352889B (es) 2011-02-25 2017-12-13 Chugai Pharmaceutical Co Ltd Anticuerpo de fc especifico para fcyriib.
WO2012154272A1 (en) 2011-02-25 2012-11-15 Wellstat Diagnostics, Llc Assays for detecting enzymatic activity
AU2012233313C1 (en) * 2011-03-30 2017-08-03 Chugai Seiyaku Kabushiki Kaisha Method for altering plasma retention and immunogenicity of antigen-binding molecule
US9023604B2 (en) 2011-07-18 2015-05-05 Iba Gmbh Method of reversibly staining a target cell
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
KR20230143201A (ko) 2011-11-30 2023-10-11 추가이 세이야쿠 가부시키가이샤 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약
SG11201404751UA (en) 2012-02-09 2014-09-26 Chugai Pharmaceutical Co Ltd Modified fc region of antibody
ES3011307T3 (en) 2012-02-23 2025-04-07 Juno Therapeutics Gmbh Chromatographic isolation of cells and other complex biological materials
WO2013149094A1 (en) 2012-03-28 2013-10-03 The Board Of Regents Of The University Of Texas System TGFβ TYPE II-TYPE III RECEPTOR FUSIONS
SG10201709559PA (en) 2012-08-24 2017-12-28 Chugai Pharmaceutical Co Ltd Fcγriib-specific fc region variant
AU2014236208B2 (en) 2013-03-14 2018-07-19 Genvivo, Inc. Thymidine kinase diagnostic assay for gene therapy applications
EP2787006B1 (de) * 2013-04-02 2018-02-28 Miltenyi Biotec GmbH Anti-CD8 Antikörper mit kalziumabhängiger Bindung
CN105246914B (zh) 2013-04-02 2021-08-27 中外制药株式会社 Fc区变体
SI3132247T1 (sl) 2014-04-16 2021-12-31 Juno Therapeutics Gmbh Postopki, kompleti in naprava za povečanje populacije celic
US11150239B2 (en) 2014-04-30 2021-10-19 Iba Lifesciences Gmbh Method of isolating a target cell
CA2981509A1 (en) 2015-03-30 2016-10-06 The Board Of Regents Of The Nevada System Of Higher Educ. On Behalf Of The University Of Nevada, La Compositions comprising talens and methods of treating hiv
WO2016166568A1 (en) 2015-04-16 2016-10-20 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells
WO2016196249A1 (en) 2015-05-29 2016-12-08 University Of Utah Research Foundation Immune tolerant and non-immune tolerant elastin-like recombinant peptides and methods of use
EA201792660A1 (ru) 2015-06-01 2018-05-31 Медиджин Иммьюнотерапиз Гмбх Библиотека т-клеточных рецепторов
EP3303392B1 (de) 2015-06-01 2020-08-05 Medigene Immunotherapies GmbH Verfahren zur erzeugung von antikörpern gegen t-zellrezeptor
AU2016341529B2 (en) 2015-10-22 2023-03-30 Juno Therapeutics Gmbh Methods for culturing cells and kits and apparatus for same
EP3365453A2 (de) 2015-10-22 2018-08-29 Juno Therapeutics GmbH Verfahren, kits, mittel und vorrichtungen zur transduktion
MX2018004875A (es) 2015-10-22 2018-08-01 Juno Therapeutics Gmbh Metodos para cultivar celulas y kits y aparatos para ello.
TWI752930B (zh) 2015-12-23 2022-01-21 德商梅迪基因免疫治療公司 抗原特異性ｔｃｒ的新生成
JP6758889B2 (ja) 2016-04-07 2020-09-23 シスメックス株式会社 標的タンパク質の精製方法
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
SG11201809903WA (en) 2016-05-16 2018-12-28 Harvard College Method for purification and activation of botulinum neurotoxin
EP3488011A1 (de) 2016-06-28 2019-05-29 Technische Universität München Kombination von reversibler und irreversibler zellmarkierung zur analyse der rezeptor-ligand-koff-rate
CA3050085A1 (en) 2017-01-20 2018-07-26 Juno Therapeutics Gmbh Cell surface conjugates and related cell compositions and methods
US11965892B2 (en) 2017-02-12 2024-04-23 Biontech Us Inc. HLA-based methods and compositions and uses thereof
CA3055200A1 (en) 2017-03-03 2018-09-07 Obsidian Therapeutics, Inc. Compositions and methods for immunotherapy
KR102746901B1 (ko) 2017-03-03 2024-12-26 옵시디안 테라퓨틱스, 인크. Cd19 조성물 및 면역요법을 위한 방법
JP7339160B2 (ja) 2017-04-27 2023-09-05 ジュノ セラピューティクス ゲーエムベーハー オリゴマー粒子試薬およびその使用方法
WO2019071150A1 (en) 2017-10-06 2019-04-11 University Of Utah Research Foundation FUSION PROTEIN FOR TARGETED THERAPY OF AUTOIMMUNE DISEASE
TWI822726B (zh) 2018-02-26 2023-11-21 德商梅迪基因免疫治療公司 Ｎｙｅｓｏ ｔ細胞受體
WO2019241315A1 (en) 2018-06-12 2019-12-19 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
EP3833681A1 (de) 2018-08-06 2021-06-16 Medigene Immunotherapies GmbH Ha-1-spezifische t-zell-rezeptoren und deren verwendung
US12516099B2 (en) 2018-08-09 2026-01-06 Juno Therapeutics, Inc. Processes for generating engineered cells and compositions thereof
US20210246189A1 (en) 2018-09-03 2021-08-12 Technische Universitaet Muenchen A double peptide tag combining reversibility and flexible functionalization
US20210386788A1 (en) 2018-10-24 2021-12-16 Obsidian Therapeutics, Inc. Er tunable protein regulation
SG11202104355SA (en) 2018-10-31 2021-05-28 Juno Therapeutics Gmbh Methods for selection and stimulation of cells and apparatus for same
KR20240091046A (ko) 2018-12-21 2024-06-21 바이오엔테크 유에스 인크. Hla 클래스 ii-특이적 에피토프 예측 및 cd4+ t 세포 특징화를 위한 방법 및 시스템
MX2021010840A (es) 2019-03-08 2022-01-19 Obsidian Therapeutics Inc Composiciones de anhidrasa carbónica 2 (ca2) humana y métodos de regulación ajustable.
EP3714941A1 (de) 2019-03-27 2020-09-30 Medigene Immunotherapies GmbH Mage-a4-tcrs
TWI850360B (zh) 2019-04-04 2024-08-01 德商梅迪基因免疫治療公司 黑色素瘤相關抗原１（ｍａｇｅａ１）特異性ｔ細胞受體及其用途
EP3983537A1 (de) 2019-06-12 2022-04-20 Obsidian Therapeutics, Inc. Ca2-zusammensetzungen und verfahren zur abstimmbaren regulierung
JP2022537670A (ja) 2019-06-12 2022-08-29 オブシディアン セラピューティクス， インコーポレイテッド Ｃａ２の組成物および調整可能な制御方法
KR20220052910A (ko) 2019-07-09 2022-04-28 메디진 이뮤노테라피스 게엠바하 Ｍａｇｅａ10 특이적 ｔ 세포 수용체 및 이의 용도
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
KR20220101641A (ko) 2019-10-30 2022-07-19 주노 테라퓨틱스 게엠베하 세포 선택 및/또는 자극 장치 및 사용 방법
WO2021152178A1 (en) 2020-01-31 2021-08-05 Cell.Copedia GmbH Methods of isolating a biological entity
BR112023005296A2 (pt) 2020-09-24 2023-04-25 Medigene Immunotherapies Gmbh Receptores de células t específicos de mage-a3 e uso dos mesmos
WO2022235929A1 (en) 2021-05-05 2022-11-10 Radius Pharmaceuticals, Inc. Animal model having homologous recombination of mouse pth1 receptor
JP2024517863A (ja) 2021-05-06 2024-04-23 ジュノ・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 細胞を刺激し、形質導入する方法
EP4334331A1 (de) 2021-05-07 2024-03-13 Medigene Immunotherapies GmbH Kombination aus prame-spezifischen t-zell-rezeptoren und chimären costimulatorischen rezeptoren
GB202107222D0 (en) 2021-05-20 2021-07-07 Quell Therapeutics Ltd Method of treg isolation
WO2023017115A1 (en) 2021-08-11 2023-02-16 Iba Lifesciences Gmbh Fractionation of cells based on a marker protein
WO2023025779A1 (en) 2021-08-25 2023-03-02 Medigene Immunotherapies Gmbh Combination of antigen specific t cell receptors and chimeric co-stimulatory receptors
US20250297282A1 (en) 2022-05-05 2025-09-25 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
US20260055159A1 (en) 2022-08-23 2026-02-26 Medigene Immunotherapies Gmbh Combination of ny-eso-1 specific t cell receptors and chimeric co-stimulatory receptors
WO2024100604A1 (en) 2022-11-09 2024-05-16 Juno Therapeutics Gmbh Methods for manufacturing engineered immune cells
JP2026504491A (ja) 2023-02-03 2026-02-05 ツェー３エス２ ゲーエムベーハー 操作された免疫細胞の非ウイルス的製造のための方法
GB202307533D0 (en) 2023-05-19 2023-07-05 Quell Therapeutics Ltd Method of treg isolation
WO2025219541A1 (en) 2024-04-19 2025-10-23 Medigene Immunotherapies Gmbh Constant uni-tabs
EP4635976A1 (de) 2024-04-19 2025-10-22 Medigene Immunotherapies GmbH Konstante uni-laschen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4571421A (en) * 1979-11-05 1986-02-18 Genentech, Inc. Mammalian gene for microbial expression
US4532207A (en) * 1982-03-19 1985-07-30 G. D. Searle & Co. Process for the preparation of polypeptides utilizing a charged amino acid polymer and exopeptidase
US4681848A (en) * 1982-09-22 1987-07-21 Takeda Chemical Industries, Ltd. Novel peptide and use thereof
US4703004A (en) * 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
EP0195680A3 (de) * 1985-03-21 1987-06-10 Immunex Corporation Proteinsynthese mit einem Identifizierungspeptid

Also Published As

Publication number Publication date
US4851341A (en) 1989-07-25
JP2665359B2 (ja) 1997-10-22
WO1988004692A1 (en) 1988-06-30
AU1056188A (en) 1988-07-15
JPH02501112A (ja) 1990-04-19
CA1307752C (en) 1992-09-22
DE3789873D1 (de) 1994-06-23
DE3789873T2 (de) 1994-09-01
EP0335899A1 (de) 1989-10-11
EP0335899A4 (de) 1990-02-06
EP0335899B1 (de) 1994-05-18

Similar Documents

Publication Publication Date Title
ATE105867T1 (de) Immunaffinitäts-reinigungssystem.
DK532284A (da) Fremgangsmaade til bestemmelse af antigenaktive aminosyresekvenser
EP0150735A3 (en) Method and composition for preparation of factor viiic
PT82132A (en) Process to determine sequences of amino acids of polypeptides complementary polypeptides or proteins which have a sequence o f amino acids or a coded sequence of nucleotides at least part ially known
DE69432033D1 (de) Adrenomedullin
ATE171216T1 (de) Expression und reinigung von rekombinantem, löslichem gewebefaktor
DK0531300T3 (da) Variant-CD44-overfladeproteiner, DNA-sekvenser, som koder herfor, antistoffer mod disse proteiner samt deres anvendelse til diagnostik og terapi
PT81445B (pt) Processo para a dissociacao de peptideos e proteinas na ligacao metionilo
Bjerrum et al. Analysis of partially degraded proteins by quantitative immunoelectrophoresis
DE68928704D1 (de) Gruppe von getrennten peptiden
DE68918323D1 (de) Spezifische Spaltung von Peptidbindungen durch organische tertiäre Phosphine mit nukleophilen Seitenketten.
SE8803986D0 (sv) Method for sequencing peptides or proteins

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee